Hanmi Pharm. Co., Ltd.

Hanmi Science Co., Ltd.

Hanmi Holdings Co., Ltd.

Hanmi Pharmaceutical Co., Ltd.

Hanmi Science

Ji Sook Kim

Young Gil Ahn

In Hwan Bae

Jae Yul Choi

Moon Sub Lee

Kwee Hyun Suh

Seok Jong Kang

Ji Young Song

Young Ho Moon

Won Jeoung Kim

Nam Du Kim

Gwan Sun Lee

Young-Kil Chang

Young Kil Chang

Han Kyong Kim

Sang Min Yun

Jae Ho Yoo

Dong Jin Hong

Jung Beom Son

Chang Hee Park

Seung Hyun Jung

Young Hee Jung

Cheol Kyung Kim

Eun Young Byun

Eun Jung Lim

Hee Cheol Kim

Jaeho Yoo

Weon Ki Yang

Wook Jang

Chang Ju Choi

Ji-Yeon Chang

Jung Soo Nam

Min Jeong Kim

Provided is a compound selected from a compound of chemical formula 1 having lysine-specific demethylase-1 (LSD1) inhibitory activity, and a tautomer, a stereoisomer, and a solvate thereof, and pharmaceutically acceptable salts of the aforementioned components. The compound is effective in the prevention or treatment of diseases caused by abnormal activation of LSD1. Also disclosed is a composition containing the compound as an active ingredient and its uses in preventing and/or treating diseases caused by abnormal activation of LSD1.

Imidazopyridine derivative compounds and use of same

Provided are a pharmaceutical composition for treating acute myeloid leukemia (AML), the pharmaceutical composition containing an Fms-like tyrosine kinase (Fms-like tyrosine kinase-3: FLT3) inhibitor or a pharmaceutically acceptable salt or solvate thereof, and a hypomethylating agent (HMA) or a pharmaceutically acceptable salt or solvate thereof in a therapeutically effective combination, and a method of treating AML using the composition.

Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Provided are a pyrimidine compound represented by Formula 1, a method of preparing the compound, and a pharmaceutical use of the compound for the prevention or treatment of cancer.

Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same

Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1.

Pyrazole derivative compound and use thereof

A novel imidazopyridine derivative compound and uses thereof are disclosed. An imidazopyridopyridine derivative compound of Chemical Formula 1 having selective inhibitory activity for a fibroblast growth factor receptor (FGFR) and a pharmaceutical composition including the compound are disclosed: 

Imidazopyridopyrimidine derivative compound and use thereof

The present invention relates to a novel bicyclic derivative that has an inhibitory activity against sodium-glucose linked transporters (SGLTs) present in the intestines and kidneys, or a pharmaceutically acceptable salt, isomer, hydrate or solvate thereof, and a pharmaceutical composition including the same as an active ingredient, which effectively inhibit the SGLT activity, and thus can be used as a therapeutic agent to treat diseases caused by hyperglycemia, such as diabetes including insulin-dependent diabetes (type I diabetes mellitus) and non-insulin-dependent diabetes (type II diabetes mellitus), diabetic complications, and obesity.

Bicyclic derivatives and pharmaceutical composition including the same

The present invention relates to a bicyclic compound for modulating G protein-coupled receptors. The inventive compound provides preventing or treating a disease associated with the modulation of G protein-coupled receptors, particularly GPR119 G protein-coupled receptors.

Bicyclic compound for modulating G protein-coupled receptors

The present invention relates to a high-yield method for preparing highly pure (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone using a metal salt of (2S,3S,5R)-2-hexyl-3,5-dihydroxyhexadecanoic acid as an intermediate.

Method for preparing (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used therefor

Optically pure voriconazole can be prepared in a high yield by a) subjecting 1-(2,4-difluorophenyl)-2(1H-1,2,4-triazol-1-yl)ethanone to Reformatsky-type coupling reaction with a substituted thiopyrimidine derivative to obtain a desired (2R,3S)/(2S,3R)-enantiomeric pair; b) removing the thiol derivative from the enantiomer to obtain racemic voriconazole; and c) isolating the racemic voriconazole by way of optical resolution using an optically active acid.

Process for preparing voriconazole

Provided is a method of preparing a (6R)-3-hexyl-4-hydroxy-6-undecyl-5,6-dihydropyran-2-one, and a (5R)-2-hexyl-5-hydroxy-3-iminohexadecanoate derivative used in said method as an intermediate.

Method of preparing (6R)-3-hexyl-4-hydroxy-6-undecyl-5, 6-dihydropyran-2-one, and intermediate used in the method

Growing community of inventors

Yeoju-gun, South Korea

Ji Sook Kim